iX Biopharma has announced a non-binding term sheet with Orion Specialty Labs to form a joint venture in the U.S. iX will own 75 percent of the venture while Orion takes 25 percent and covers the capital costs. The goal is to use Orion’s existing FDA-licensed facilities to bring iX’s WaferiX technology to market faster, with pilot production aimed for the second half of 2026. The deal is not yet final, and there’s no expected immediate financial impact for iX.���������
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
